Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a...
Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun...
Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received separate clinical...
Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion
Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive...
Boston Scientific, Danaher, and Siemens Healthineers Launch A3 International Medical Technology Innovation Center at Shanghai Eastern Hub
The Global Medical Device Training, Exhibition, Trading and Innovation Center was officially inaugurated this week...
Shanghai Henlius Biotech Initiates Phase II/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a...
Hengrui Pharmaceuticals and Kailera Therapeutics Report Strong Phase III Results for Oral GLP-1 Agonist HRS-7535 in Type 2 Diabetes
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) and its U.S. partner Kailera Therapeutics...
Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research
Insilico Medicine (HKG: 3696) and Human Life Foundation Models (HLFM), a newly established spin-off from...
Shanghai Henlius Biotech Doses First Patient in China for Global Phase I Study of Daratumumab Biosimilar HLX15-SC in Multiple Myeloma
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in China...
Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics
Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics...
Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform
Shanghai Simpletouch Robot Co., Ltd. has filed its prospectus with the Hong Kong Stock Exchange...
Qingfeng Pharmaceutical Secures Greater China Rights to Merz’s Inbrija Levodopa Inhalation Powder for Parkinson’s Disease OFF Episodes
Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German...
Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China
Peak Pharmaceutical Co., Ltd. announced a strategic partnership with SPH Kyuan Trade, a core subsidiary...
Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis
Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has...
NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking
China’s National Medical Products Administration (NMPA) has released the “Compliance Guidelines for Online Retail of...
Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical...
CanSino Biologics Initiates Phase I/II Trial for PCV24 Pneumococcal Conjugate Vaccine with Enhanced Serotype Coverage
CanSino Biologics Inc. (HKG: 6185) announced the initiation of its Phase I/II clinical study for...
China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn’s Disease
China Medical System Holdings Limited (CMS, HKG: 0867) announced it has received clinical trial authorization...
MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System – Advanced Solution for Complex Neurovascular Lesions
MicroPort NeuroTech Limited (HKG: 2172) announced it has received marketing approval from the U.S. Food...
Eli Lilly Reports Positive Phase 1b Results for VERVE-102 Base Editing Therapy with Sustained LDL-C Reductions Up to 18 Months
Eli Lilly and Company (NYSE: LLY) announced positive interim results from the Phase 1b Heart-2...